PGR positive

P=N/A, N=550, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P3, N=3100, Suspended, Novartis Pharmaceuticals | Recruiting --> Suspended

Circulating levels of the chemokine CXCL1 were elevated only in animals with tumors containing HRASG12V mutation. Since RAS pathway aberrations are found in 19% of cancers, evaluating skeletal muscle defects in the context of genomic aberrations in cancers, particularly RAS pathway mutations, may accelerate development of therapeutic modalities to overcome cancer-induced systemic effects.

Our findings indicate that men with breast cancer are diagnosed at an older age than women, and that men have a more advanced stage than women at the time of diagnosis. The histopathology and expression of biomarkers of breast cancer differ between men and women.

P1, N=33, Recruiting, Mayo Clinic | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2027

P1, N=22, Completed, Barbara Parker, MD | Active, not recruiting --> Completed | Phase classification: P1b --> P1

P=N/A, N=1167, Recruiting, Breast Cancer Trials, Australia and New Zealand | Phase classification: P3 --> P=N/A | Trial completion date: Dec 2023 --> Apr 2026 | Trial primary completion date: Dec 2023 --> Oct 2025

P=N/A, N=2000, Recruiting, University Hospital Augsburg | Not yet recruiting --> Recruiting

P=N/A, N=256, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P2, N=99, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025

Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.

Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic, or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy. Summary Statement This study activated on 10/30/2023. As of December 31, 2023, there had been five patients registered to MammaPrint screening step, all of whom did not to go on to randomization due to ineligible MammaPrint status.

P=N/A, N=739, Recruiting, SWOG Cancer Research Network | Trial completion date: Jan 2038 --> Dec 2036 | Trial primary completion date: Jan 2035 --> Dec 2030

Using an established human primary cell culture model, we previously demonstrated that the promyelocytic leukemia zinc finger (PLZF) transcription factor is a direct target of the progesterone receptor (PGR) and is essential for progestin-dependent decidualization of human endometrial stromal cells (HESCs)...In addition to a defect in P4-dependent receptivity, the Plzf d/d endometrium fails to undergo decidualization in response to an artificial decidual stimulus, providing the in vivo validation for our earlier HESC culture findings. Collectively, our new Plzf d/d mouse model underscores the physiological importance of the PLZF transcription factor not only in endometrial stromal cell decidualization but also uterine receptivity, two uterine cellular processes that are indispensable for the establishment of pregnancy.

These findings demonstrate signs of a grade change for screen-detected invasive breast cancers early in the pandemic, with recovery evident in 2021, and without an increase in nodal positivity. Future studies are needed to determine the COVID-19 impact on long-term breast cancer outcomes including mortality.

P1/2; N=204 --> 24 | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Jun 2023

P1, N=35, Active, not recruiting, National Cancer Institute (NCI)

P2, N=42, Terminated, Theodoros Foukakis | Active, not recruiting --> Terminated; Slow accrual

P1, N=20, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Unknown status --> Completed

Age, ethnicity, histological grade, radiotherapy, tumor size, ER status, SLN status, and marital status were independent risk factors for Breast cancer specific survival (BCSS). Moreover, the survival rate of patients with 3 positive SLNs was not significantly different from that with one or two positive SLNs, We concluded that patients with stage N1 breast cancer were exempt from axillary lymph node dissection, which is worthy of further study.

P3; Trial completion date: Dec 2027 --> Mar 2028

Our patients presented late: axilla was commonly involved and a third had advanced disease. Screening and community awareness programs may help in early detection. Hormone use for contraception needs to be weighed carefully. Better data collection may help in designing screening and care programs.

Further study into the pathogenesis of fibroadenoma is required to understand the role of ER and PR and explore the therapeutic potential of such drugs that affects these receptors. Cabling.

P3, N=3100, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

P=N/A, N=50, Recruiting, Stanford University | N=21 --> 50

P2, N=114, Active, not recruiting, Beth Israel Deaconess Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Jul 2024

P2, N=2, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial completion date: Dec 2023 --> Jun 2023

ER and PR staining show a high level of concordance (97.3% and 87.1%, respectively) between IBC and DCIS. HER2 showed a slight trend toward increased staining in DCIS, however, only 4 of the 147 cases (2.7%) were 3+ with an associated HER2 negative IBC. Our findings suggest that ER, PR, and HER2 show concordance between IBC and DCIS, with only a slight increase in HER2 staining in DCIS.

P3, N=3100, Not yet recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jul 2028 --> Sep 2029

P=N/A, N=75, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Jul 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Mar 2025

P2, N=36, Recruiting, Medical College of Wisconsin | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025

P=N/A, N=42, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=72, Active, not recruiting, Centre Leon Berard | Trial completion date: Dec 2023 --> Dec 2024

P3, N=632, Completed, Fondazione Michelangelo | Trial completion date: Jan 2024 --> Mar 2023

P=N/A, N=208, Active, not recruiting, IceCure Medical Ltd. | Trial completion date: Dec 2024 --> Jun 2024 | Trial primary completion date: Aug 2024 --> Mar 2024

P=N/A, N=739, Recruiting, SWOG Cancer Research Network | N=1320 --> 739

P1, N=139, Active, not recruiting, AstraZeneca | Phase classification: P1b --> P1

P3, N=287, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

OBC is a rare breast disease whose diagnosis and treatment are currently controversial. There was no significant difference in the efficacy of other less invasive surgical procedures compared to those of modified radical mastectomy. In addition, radiotherapy can significantly improve patient outcomes. We should pay attention to the psychological state of patients while they receive antitumor therapy.

P3, N=532, Recruiting, DualityBio Inc. | Not yet recruiting --> Recruiting

P1, N=373, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting

P=N/A, N=200, Completed, Capital Medical University | Unknown status --> Completed